CD19 (B-lymphocyte antigen CD19) variants and mutations
CD19 (also known as B-lymphocyte antigen CD19) is a human protein-coding gene encoding a b-lymphocyte antigen protein. It amplifies B-cell receptor signaling and helps set the threshold for B-cell activation throughout much of B-cell development. Loss-of-function variants can cause antibody deficiency, while its lineage-restricted surface expression makes it a major target for monoclonal antibodies and CAR-T therapy. This analysis covers 852 CD19 variants and mutations. Of these, 87% have computational variant effect predictions. Disease context includes immunodeficiency, common variable, 3, diffuse large B-cell lymphoma, and common variable immunodeficiency. Example CD19 variants include P2L, P2S, and P3T.
Variant analysis overview
- Gene: CD19
- Protein: B-lymphocyte antigen CD19
- UniProt accession: P15391
- Organism: Homo sapiens
- Variants analyzed: 852
- Variant scope: all variants
- Completed: 2026-08-22
Variant and mutation evidence
- Variant composition: 569 unspecified-consequence records; 140 missense variants; 5 in-frame deletions; 114 synonymous variants; 3 in-frame insertions; 10 frameshift variants; 3 splice-region variants; 6 stop-gained variants; 2 substitution
- Prediction scores: 744 variants have prediction scores (87% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: immunodeficiency, common variable, 3, diffuse large B-cell lymphoma, common variable immunodeficiency, acute lymphoblastic leukemia, neuromyelitis optica, mantle cell lymphoma, follicular lymphoma, neoplasm, B-cell acute lymphoblastic leukemia, agammaglobulinemia, Decreased circulating immunoglobulin concentration, recurrent infections associated with rare immunoglobulin isotypes deficiency.
Protein structure and variant hotspots
- Protein features: 1 transmembrane segments; 2 domains; 12 post-translational modification sites.
- Structural context: 371 variants have structural context.
- PTM context: 16 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, ClinGen, MaveDB, LitVar.
Notable CD19 variants
Examples include P2L, P2S, P3T, P3S, P3P, P4S, p.Pro4del, P4P. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- P2L (p.Pro2Leu), ExAC rs766808956, gnomAD rs766808956, REVEL 0.09, MetaLR 0.11
- P2S (p.Pro2Ser), gnomAD 16-28932004-C-T, REVEL 0.08, CADD 16.30
- P3T (p.Pro3Thr), gnomAD 16-28932007-C-A, REVEL 0.15, CADD 6.73
- P3S (p.Pro3Ser), gnomAD 16-28932007-C-T, REVEL 0.10, CADD 1.78
- P3P (p.Pro3Pro), gnomAD 16-28932009-T-G, CADD 6.97
- P4S (p.Pro4Ser), Ensembl rs1964646858, REVEL 0.06, MetaLR 0.08
- P4del (p.Pro4del), rs1325173363, gnomAD 16-28932006-ACCT-, CADD 13.90
- P4P (p.Pro4Pro), rs751182393, gnomAD 16-28932012-T-C, CADD 8.41
- R5C (p.Arg5Cys), rs556457823, ClinGen CA7988250, NCI-TCGA Cosmic COSV6118, cosmic curated COSV61189, REVEL 0.04, MetaLR 0.04, Conflicting interpretations, not provided; Inborn genetic diseases
- R5H (p.Arg5His), rs781764596, ClinGen CA7988251, NCI-TCGA Cosmic COSV1044, cosmic curated COSV10441, REVEL 0.06, MetaLR 0.03, Uncertain significance, Inborn genetic diseases; not provided
- R5L (p.Arg5Leu), ExAC rs781764596, gnomAD rs781764596, REVEL 0.03, MetaLR 0.02, Uncertain significance
- R5P (p.Arg5Pro), ExAC rs781764596, gnomAD rs781764596, Uncertain significance
- R5S (p.Arg5Ser), 1000Genomes rs556457823, ExAC rs556457823, TOPMed rs556457823, gnomAD rs556457823, Likely benign
- R5R (p.Arg5Arg), rs748727571, gnomAD 16-28932015-C-A, CADD 3.53
- L6R (p.Leu6Arg), rs886051886, ClinGen CA10647298, ClinVar RCV000406915, gnomAD rs886051886, REVEL 0.09, MetaLR 0.05, Uncertain significance, Immunodeficiency, common variable, 3
- L7del (p.Leu7del), gnomAD 16-28932014-GCCT-, CADD 7.46
- F8L (p.Phe8Leu), rs1567503993, ClinGen CA395428722, ClinVar RCV003144714, REVEL 0.05, MetaLR 0.06, Uncertain significance, Immunodeficiency, common variable, 3
- F8F (p.Phe8Phe), rs1567503993, gnomAD 16-28932024-C-T, CADD 6.11
- F9del (p.Phe9del), gnomAD 16-28932019-CTCT-, CADD 8.97
- F9L (p.Phe9Leu), gnomAD 16-28932025-T-C, REVEL 0.03, CADD 5.67
- F9F (p.Phe9Phe), rs756130951, gnomAD 16-28932027-C-T, CADD 7.97
- L10F (p.Leu10Phe), gnomAD 16-28932028-C-T, REVEL 0.03, CADD 16.90
- L10L (p.Leu10Leu), rs143861592, gnomAD 16-28932030-C-T, CADD 7.09
- L11F (p.Leu11Phe), rs749441583, ClinGen CA7988256, cosmic curated COSV10590, ClinVar RCV002012807, REVEL 0.20, MetaLR 0.20, Uncertain significance, not provided
- p.Leu11dup, gnomAD 16-28932025-T-TTC, CADD 12.10
- L11L (p.Leu11Leu), rs1472253807, gnomAD 16-28932033-C-G, CADD 7.83
- F12S (p.Phe12Ser), gnomAD 16-28932035-T-C, REVEL 0.35, CADD 25.80
- L13F (p.Leu13Phe), ESP rs377257177, ExAC rs377257177, gnomAD rs377257177, REVEL 0.21, MetaLR 0.22
- L13H (p.Leu13His), ExAC rs774087748, gnomAD rs774087748, REVEL 0.34, MetaLR 0.23
- L13P (p.Leu13Pro), ExAC rs774087748, gnomAD rs774087748, REVEL 0.36, MetaLR 0.23
- L13L (p.Leu13Leu), gnomAD 16-28932039-C-T, CADD 0.54
- T14A (p.Thr14Ala), TOPMed rs1258141013, gnomAD rs1258141013, REVEL 0.02, MetaLR 0.07
- T14N (p.Thr14Asn), TOPMed rs1188604193, Uncertain significance, Inborn genetic diseases
- T14P (p.Thr14Pro), gnomAD 16-28932040-A-C, REVEL 0.13, CADD 19.50
- T14I (p.Thr14Ile), gnomAD 16-28932041-C-T, REVEL 0.04, CADD 7.53
- T14T (p.Thr14Thr), gnomAD 16-28932042-C-G, CADD 2.04
- P15P (p.Pro15Pro), gnomAD 16-28932045-C-T, CADD 0.56
- M16I (p.Met16Ile), TOPMed rs1483752320, gnomAD rs1483752320
- M16T (p.Met16Thr), rs745681190, ClinGen CA7988259, ClinVar RCV001267750, ExAC rs745681190, REVEL 0.14, MetaLR 0.03, Likely benign, Immunodeficiency, common variable, 3
- M16K (p.Met16Lys), gnomAD 16-28932047-T-A, REVEL 0.15, CADD 0.87
- V18I (p.Val18Ile), gnomAD 16-28932052-G-A, REVEL 0.04, CADD 9.47
- V18V (p.Val18Val), rs1427495600, gnomAD 16-28932054-C-G, CADD 3.51
- P20A (p.Pro20Ala), TOPMed rs1028550245, gnomAD rs1028550245, REVEL 0.05, MetaLR 0.06
- P20L (p.Pro20Leu), gnomAD 16-28932059-C-T, REVEL 0.13, CADD 16.00
- P20P (p.Pro20Pro), rs1199583472, gnomAD 16-28932060-C-G, CADD 4.11
- E21K (p.Glu21Lys), rs771929657, NCI-TCGA Cosmic COSV1002, cosmic curated COSV10021, ExAC rs771929657, REVEL 0.06, MetaLR 0.06, Uncertain significance, not specified
- E21Q (p.Glu21Gln), rs771929657, ClinGen CA395428842, ClinVar RCV001116544, ClinVar RCV002556465, REVEL 0.05, MetaLR 0.03, Uncertain significance, not provided; Immunodeficiency, common variable, 3
- E21G (p.Glu21Gly), gnomAD 16-28932062-A-G, REVEL 0.03, CADD 16.10
- E22K (p.Glu22Lys), gnomAD 16-28932064-G-A, REVEL 0.02, CADD 0.36
- E22V (p.Glu22Val), gnomAD 16-28932065-A-T, REVEL 0.15, CADD 22.80
- P23S (p.Pro23Ser), TOPMed rs1275186898, gnomAD rs1275186898
- P23T (p.Pro23Thr), TOPMed rs1275186898, gnomAD rs1275186898, REVEL 0.06, MetaLR 0.05
- P23L (p.Pro23Leu), gnomAD 16-28932068-C-T, REVEL 0.03, CADD 3.55
- L24L (p.Leu24Leu), rs1473017630, gnomAD 16-28932070-C-T, CADD 1.15
- V25A (p.Val25Ala), ExAC rs775402324, gnomAD rs775402324, REVEL 0.02, MetaLR 0.06
- V25* (p.Val25Ter), gnomAD 16-28932067-C-CCT, CADD 17.10
- V26A (p.Val26Ala), ExAC rs760726729, gnomAD rs760726729
- V26M (p.Val26Met), gnomAD rs1964650090, REVEL 0.04, MetaLR 0.03
- K27R (p.Lys27Arg), cosmic curated COSV61188, ExAC rs763492717, TOPMed rs763492717, gnomAD rs763492717, REVEL 0.04, MetaLR 0.02
- K27T (p.Lys27Thr), ExAC rs763492717, TOPMed rs763492717, gnomAD rs763492717
- K27K (p.Lys27Lys), rs1321374095, gnomAD 16-28932081-G-A, CADD 8.00
- V28V (p.Val28Val), rs776234385, gnomAD 16-28932084-G-A, CADD 4.68
- E29Q (p.Glu29Gln), ExAC rs761320831, TOPMed rs761320831, gnomAD rs761320831, REVEL 0.05, MetaLR 0.03, Uncertain significance, Immunodeficiency, common variable, 3; Inborn genetic diseases
- E30D (p.Glu30Asp), ExAC rs769495907, TOPMed rs769495907, gnomAD rs769495907, REVEL 0.21, MetaLR 0.08
- E30E (p.Glu30Glu), rs769495907, gnomAD 16-28932347-G-A, CADD 15.30
- G31* (p.Gly31Ter), TOPMed rs1348223584, gnomAD rs1348223584, CADD 36.00
- D32N (p.Asp32Asn), rs151258764, ClinGen CA7988288, ClinVar RCV002570937, ESP rs151258764, REVEL 0.05, MetaLR 0.08, Uncertain significance, not provided
- N33H (p.Asn33His), Ensembl rs1964658684
- N33I (p.Asn33Ile), ExAC rs762741803, TOPMed rs762741803, gnomAD rs762741803, REVEL 0.10, MetaLR 0.04
- N33N (p.Asn33Asn), rs767961417, gnomAD 16-28932356-C-T, CADD 0.57
- N33K (p.Asn33Lys), gnomAD 16-28932356-C-A, REVEL 0.02, CADD 0.22
- A34T (p.Ala34Thr), gnomAD rs1177666606, REVEL 0.21, MetaLR 0.16
- V35M (p.Val35Met), rs1417395113, ClinGen CA395429592, ClinVar RCV002642646, TOPMed rs1417395113, REVEL 0.02, MetaLR 0.02, Uncertain significance, not provided
- V35V (p.Val35Val), rs1178392991, gnomAD 16-28932362-G-A, CADD 3.71
- L36L (p.Leu36Leu), rs934151410, gnomAD 16-28932365-G-A, CADD 5.57
- Q37R (p.Gln37Arg), ExAC rs753138134, gnomAD rs753138134, REVEL 0.02, MetaLR 0.02
- C38Y (p.Cys38Tyr), gnomAD 16-28932370-G-A, REVEL 0.76, CADD 24.80
- L39F (p.Leu39Phe), gnomAD rs1434266587, REVEL 0.07, MetaLR 0.02
- L39V (p.Leu39Val), gnomAD 16-28932372-C-G, REVEL 0.13, CADD 21.00
- L39L (p.Leu39Leu), gnomAD 16-28932374-C-T, CADD 1.32
- K40R (p.Lys40Arg), rs906793959, ClinGen CA279269293, ClinVar RCV002610631, TOPMed rs906793959, REVEL 0.03, MetaLR 0.05, Uncertain significance, not provided
- G41R (p.Gly41Arg), gnomAD rs1372743235, REVEL 0.09, MetaLR 0.08
- T42A (p.Thr42Ala), gnomAD rs1964660150, REVEL 0.02, MetaLR 0.02
- T42I (p.Thr42Ile), TOPMed rs1174480734, gnomAD rs1174480734, REVEL 0.06, MetaLR 0.02
- T42T (p.Thr42Thr), rs1410878626, gnomAD 16-28932383-C-G, CADD 4.28
- S43* (p.Ser43Ter), rs2152228184, ClinGen CA395429742, ClinVar RCV001896860, Ensembl rs2152228184, CADD 28.00, Pathogenic
- D44N (p.Asp44Asn), ExAC rs761039208, TOPMed rs761039208, gnomAD rs761039208, REVEL 0.03, MetaLR 0.03, Uncertain significance
- D44Y (p.Asp44Tyr), rs761039208, ClinGen CA7988292, ClinVar RCV003210170, ExAC rs761039208, REVEL 0.09, MetaLR 0.03, Uncertain significance, Inborn genetic diseases
- D44D (p.Asp44Asp), rs1371894984, gnomAD 16-28932389-T-C, CADD 1.87
- D44E (p.Asp44Glu), gnomAD 16-28932389-T-A, REVEL 0.02, CADD 0.87
- G45S (p.Gly45Ser), gnomAD 16-28932390-G-A, REVEL 0.04, CADD 5.90
- G45G (p.Gly45Gly), gnomAD 16-28932392-C-A, CADD 2.03
- P46S (p.Pro46Ser), gnomAD 16-28932393-C-T, REVEL 0.01, CADD 0.57
- T47I (p.Thr47Ile), rs375965055, ClinGen CA7988293, ClinVar RCV004433256, ESP rs375965055, REVEL 0.02, MetaLR 0.02, Uncertain significance, Inborn genetic diseases
- T47N (p.Thr47Asn), rs375965055, ClinGen CA7988294, ClinVar RCV002647102, ESP rs375965055, REVEL 0.03, MetaLR 0.02, Uncertain significance, not provided
- T47A (p.Thr47Ala), gnomAD 16-28932396-A-G, REVEL 0.02, CADD 0.00
- T47T (p.Thr47Thr), gnomAD 16-28932398-T-G, CADD 1.48
- Q48H (p.Gln48His), ExAC rs757328326, gnomAD rs757328326, REVEL 0.04, MetaLR 0.02
- Q49* (p.Gln49Ter), Ensembl rs1596712490
- Q49Q (p.Gln49Gln), rs140445039, gnomAD 16-28932404-G-A, CADD 0.55
- L50L (p.Leu50Leu), gnomAD 16-28932405-C-T, CADD 3.95
- L50Q (p.Leu50Gln), gnomAD 16-28932406-T-A, REVEL 0.15, CADD 17.40
- T51S (p.Thr51Ser), gnomAD 16-28932408-A-T, REVEL 0.04, CADD 1.49
- T51A (p.Thr51Ala), gnomAD 16-28932408-A-G, REVEL 0.02, CADD 0.15
- T51I (p.Thr51Ile), gnomAD 16-28932409-C-T, REVEL 0.03, CADD 4.92
- W52C (p.Trp52Cys), rs886037920, ClinGen CA10586369, ClinVar RCV000240828, Ensembl rs886037920, AlphaMissense 0.98, MetaLR 0.36, Pathogenic, Immunodeficiency, common variable, 3
- W52* (p.Trp52Ter), gnomAD 16-28932412-G-A, CADD 35.00
- S53C (p.Ser53Cys), ExAC rs750625293, TOPMed rs750625293, gnomAD rs750625293, REVEL 0.02, MetaLR 0.01
- S53F (p.Ser53Phe), ExAC rs750625293, TOPMed rs750625293, gnomAD rs750625293
- S53S (p.Ser53Ser), gnomAD 16-28932416-T-C, CADD 4.17
- R54L (p.Arg54Leu), cosmic curated COSV61188, ESP rs150438147, ExAC rs150438147, TOPMed rs150438147, REVEL 0.08, MetaLR 0.03
- R54Q (p.Arg54Gln), ESP rs150438147, ExAC rs150438147, TOPMed rs150438147, gnomAD rs150438147, REVEL 0.10, MetaLR 0.02
- R54W (p.Arg54Trp), rs758662669, ClinGen CA7988298, NCI-TCGA Cosmic COSV6118, cosmic curated COSV61188, REVEL 0.05, MetaLR 0.02, Uncertain significance, Inborn genetic diseases; not provided
- E55G (p.Glu55Gly), gnomAD rs1205037232
- E55E (p.Glu55Glu), rs2152228219, gnomAD 16-28932422-G-A, CADD 0.74
- S56F (p.Ser56Phe), gnomAD rs1250674037, REVEL 0.04, MetaLR 0.12
- S56T (p.Ser56Thr), gnomAD 16-28932423-T-A, REVEL 0.03, CADD 2.00
- S56S (p.Ser56Ser), rs746831063, gnomAD 16-28932425-C-A, CADD 3.69
- P57L (p.Pro57Leu), rs185062613, ClinGen CA7988301, cosmic curated COSV61188, ClinVar RCV001311439, REVEL 0.03, MetaLR 0.07, Uncertain significance, not provided; Immunodeficiency, common variable, 3
- P57R (p.Pro57Arg), gnomAD 16-28932427-C-G, REVEL 0.04, CADD 2.54
- P57P (p.Pro57Pro), rs199665700, gnomAD 16-28932428-G-A, CADD 5.76
- L58I (p.Leu58Ile), gnomAD rs1289103595, REVEL 0.03, MetaLR 0.06
- L58L (p.Leu58Leu), gnomAD 16-28932431-T-G, CADD 0.62
- K59R (p.Lys59Arg), TOPMed rs1453893043, gnomAD rs1453893043
- K59T (p.Lys59Thr), TOPMed rs1453893043, gnomAD rs1453893043, REVEL 0.03, MetaLR 0.03
- K59K (p.Lys59Lys), rs1191959854, gnomAD 16-28932434-A-G, CADD 2.42
- P60R (p.Pro60Arg), rs1349878263, ClinGen CA395429901, ClinVar RCV002903262, gnomAD rs1349878263, REVEL 0.23, MetaLR 0.16, Uncertain significance, not provided
- P60S (p.Pro60Ser), rs1010611591, ClinGen CA279269423, ClinVar RCV001027775, ClinVar RCV001862416, REVEL 0.04, MetaLR 0.06, Uncertain significance, not provided; Immunodeficiency, common variable, 3
- P60T (p.Pro60Thr), gnomAD 16-28932435-C-A, REVEL 0.05, CADD 14.40
- P60H (p.Pro60His), gnomAD 16-28932436-C-A, REVEL 0.23, CADD 22.30
- P60P (p.Pro60Pro), gnomAD 16-28932437-C-T, CADD 5.53
- K63Q (p.Lys63Gln), gnomAD rs1392302820, REVEL 0.01, MetaLR 0.01
- L64F (p.Leu64Phe), rs2506454364, ClinGen CA395429936, ClinVar RCV002815503, REVEL 0.08, MetaLR 0.05, Uncertain significance, not provided
- S65N (p.Ser65Asn), rs145255205, ClinGen CA7988303, ClinVar RCV002660594, ESP rs145255205, REVEL 0.02, MetaLR 0.02, Uncertain significance, Inborn genetic diseases
- S65R (p.Ser65Arg), gnomAD 16-28932450-A-C, REVEL 0.02, CADD 12.80
- S65S (p.Ser65Ser), rs902138712, gnomAD 16-28932452-C-T, CADD 6.86
- L66M (p.Leu66Met), Ensembl rs2152228244, REVEL 0.04, MetaLR 0.10
- L66P (p.Leu66Pro), gnomAD rs1964663290, REVEL 0.03, MetaLR 0.06
- G67G (p.Gly67Gly), gnomAD 16-28932458-G-A, CADD 3.20
- L68M (p.Leu68Met), Ensembl rs1964663388, REVEL 0.07, MetaLR 0.09
- L68L (p.Leu68Leu), rs1964663388, gnomAD 16-28932459-C-T, CADD 0.24
- P69L (p.Pro69Leu), TOPMed rs1964663650, gnomAD rs1964663650
- P69R (p.Pro69Arg), TOPMed rs1964663650, gnomAD rs1964663650, REVEL 0.04, MetaLR 0.02
- P69P (p.Pro69Pro), rs769405929, gnomAD 16-28932464-A-G, CADD 3.24
- G70D (p.Gly70Asp), rs2506454488, ClinGen CA395429992, ClinVar RCV002715224, Uncertain significance, not provided
- G70G (p.Gly70Gly), gnomAD 16-28932467-C-T, CADD 8.15
- L71V (p.Leu71Val), ESP rs149157381, ExAC rs149157381, TOPMed rs149157381, gnomAD rs149157381, REVEL 0.05, MetaLR 0.02
- L71L (p.Leu71Leu), rs762651897, gnomAD 16-28932470-G-A, CADD 6.43
- G72E (p.Gly72Glu), gnomAD 16-28932472-G-A, REVEL 0.21, CADD 22.80
- I73V (p.Ile73Val), gnomAD 16-28932474-A-G, REVEL 0.01, CADD 0.02
- I73I (p.Ile73Ile), gnomAD 16-28932476-C-T, CADD 4.54
- H74R (p.His74Arg), gnomAD rs1327207135, REVEL 0.10, MetaLR 0.06
- H74Y (p.His74Tyr), gnomAD 16-28932477-C-T, REVEL 0.10, CADD 3.49
- M75T (p.Met75Thr), ExAC rs770731258, gnomAD rs770731258, REVEL 0.05, MetaLR 0.07
- M75E (p.Met75Glu), gnomAD 16-28932479-CAT-C, CADD 22.30
- M75L (p.Met75Leu), gnomAD 16-28932480-A-C, REVEL 0.01, CADD 3.06
- R76S (p.Arg76Ser), rs999692059, ClinGen CA279269440, ClinVar RCV001336403, ClinVar RCV001871885, REVEL 0.02, MetaLR 0.04, Uncertain significance, Immunodeficiency, common variable, 3; not provided
- P77S (p.Pro77Ser), Ensembl rs1964664462
- P77T (p.Pro77Thr), gnomAD 16-28932486-C-A, REVEL 0.03, CADD 7.86
- P77P (p.Pro77Pro), rs775660739, gnomAD 16-28932488-C-A, CADD 3.31
- L78P (p.Leu78Pro), rs1366984000, ClinGen CA395430066, ClinVar RCV001320671, TOPMed rs1366984000, REVEL 0.19, MetaLR 0.12, Uncertain significance, not provided
- L78L (p.Leu78Leu), gnomAD 16-28932491-G-A, CADD 4.69
- A79T (p.Ala79Thr), gnomAD rs1214805316
- A79V (p.Ala79Val), gnomAD 16-28932493-C-T, REVEL 0.07, CADD 19.20
- A79A (p.Ala79Ala), rs761106054, gnomAD 16-28932494-C-T, CADD 7.62
- I80T (p.Ile80Thr), rs2506454776, ClinGen CA395430083, ClinVar RCV003268336, REVEL 0.04, MetaLR 0.06, Uncertain significance, Inborn genetic diseases
- L82V (p.Leu82Val), gnomAD 16-28932501-C-G, REVEL 0.40, CADD 18.80
- F83C (p.Phe83Cys), TOPMed rs1297743299
- F83S (p.Phe83Ser), gnomAD 16-28932505-T-C, REVEL 0.05, CADD 19.30
- I84T (p.Ile84Thr), TOPMed rs944597391
- F85L (p.Phe85Leu), ExAC rs764433136, gnomAD rs764433136, REVEL 0.05, MetaLR 0.02
- N86S (p.Asn86Ser), gnomAD 16-28932514-A-G, REVEL 0.34, CADD 23.50
- N86N (p.Asn86Asn), rs777186183, gnomAD 16-28932515-C-T, CADD 3.67
- V87A (p.Val87Ala), NCI-TCGA Cosmic COSV1002, cosmic curated COSV10021, TOPMed rs1821495419, Variant assessed as somatic; moderate impact.
- V87I (p.Val87Ile), 1000Genomes rs201308929, ExAC rs201308929, TOPMed rs201308929, gnomAD rs201308929, REVEL 0.07, MetaLR 0.02, Uncertain significance, Inborn genetic diseases
- V87V (p.Val87Val), gnomAD 16-28932518-C-G, CADD 6.30
- S88S (p.Ser88Ser), rs1468064603, gnomAD 16-28932521-T-G, CADD 1.59
- Q89* (p.Gln89Ter), gnomAD 16-28932522-C-T, CADD 23.50
- Q89P (p.Gln89Pro), gnomAD 16-28932523-A-C, REVEL 0.06, CADD 12.30
- Q90L (p.Gln90Leu), ExAC rs765272658, gnomAD rs765272658, REVEL 0.11, MetaLR 0.03
Public CD19 analysis runs
- CD19 analysis run — CD19 (852 variants) — completed 2026-08-22